JP2001504442A - ペプチド類の水性配合物 - Google Patents
ペプチド類の水性配合物Info
- Publication number
- JP2001504442A JP2001504442A JP50421998A JP50421998A JP2001504442A JP 2001504442 A JP2001504442 A JP 2001504442A JP 50421998 A JP50421998 A JP 50421998A JP 50421998 A JP50421998 A JP 50421998A JP 2001504442 A JP2001504442 A JP 2001504442A
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- compound
- peptide
- lhrh
- leuprolide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. a)少なくとも約10%(重量/重量)の少なくとも1種のペプチド化 合物;および b)水; を含む、ペプチド関連化合物の安定な水性配合物。 2. 少なくとも約30%(重量/重量)のペプチド化合物を含む、請求項1 の配合物。 3. 前記ペプチド化合物がLHRH−関連化合物である、請求項1の配合物 。 4. 前記ペプチド化合物がロイプロリド、LHRH、ナファレリンおよびゴ セレリンからなる群から選ばれる、請求項3の配合物。 5. 照射線照射後に安定である、請求項1の配合物。 6. 少なくとも2か月間80℃で安定である、請求項1の配合物。 7. 少なくとも3か月間37℃で安定である、請求項1の配合物。 8. 少なくとも1年間37℃で安定である、請求項1の配合物。 9. 植え込み可能な医薬送り出し器具において使用するために適合されてい る、請求項1の配合物。 10. 緩衝剤、賦形剤、溶媒、溶解化剤および保存料からなる群から選ばれ た少なくとも1種をさらに含む、請求項1の配合物。 11. 消毒蒸留水中の約30%〜約50%(重量/重量)のLHRH−関連 化合物酢酸ロイプロリドから本質的になる、請求項1の配合物。 12. ゲルを形成する、請求項1の配合物。 13. 少なくとも1種の非水性極性非プロトン性溶媒をさらに含む、請求項 1の配合物。 14. 前記非水性極性非プロトン性溶媒がDMSOまたはDMFである、請 求項13の配合物。 15. 水中に少なくとも約10%(重量/重量)の少なくとも1種のペプチ ド化合物を溶解することからなる、請求項1の安定な水性配合物を製造する方法 。 16. 少なくとも約30%(重量/重量)のペプチド化合物が溶解される、 請求項15の方法。 17. 前記ペプチド化合物が、LHRH−関連化合物である、請求項15の 方法。 18. 前記ペプチド化合物がロイプロリド、LHRH、ナファレリンおよび ゴセレリンからなる群から選ばれる、請求項17の方法。 19. 緩衝剤、賦形剤、溶媒、溶解化剤および保存料からなる群から選ばれ る少なくとも1種を添加する工程をさらに含む、請求項15の方法。 20. 約30%〜約50%(重量/重量)のLHRH−関連化合物酢酸ロイ プロリドが消毒蒸留水中に溶解される、請求項15の方法。 21. 少なくとも1種の非水性極性非プロトン性溶媒を加える工程をさらに 含む、請求項15の方法。 22. 前記非水性極性非プロトン性溶媒がDMSOまたはDMFである、請 求項21の方法。 23. 請求項1の配合物の有効量を下記患者に投与することからなる、ペプ チド化合物の投与により緩和されることが出来る症状を患っている患者を治療す る方法。 24. 前記投与が非経口投与である、請求項23の方法。 25. 前記投与が長期間の連続投与である、請求項23の方法。 26. 前記投与が植え込み可能な医薬送り出し器具の使用によって行われる 、請求項25の方法。 27. 前記症状が前立腺癌でありそして前記ペプチド化合物がロイプロリド である、請求項23の方法。 28. 少なくとも約80ミクログラムのロイプロリドが毎日投与される、請 求項23の方法。 29. 3か月、6か月および12か月からなる群から選ばれる期間、前記毎 日の投与が続けられる、請求項28の方法。 30. 前記期間の前記毎日の投与が、植え込み可能な医薬送り出しシステム を用いて行われる連続投与である、請求項29の方法。 31. 前記症状が前立腺癌でありそして前記ペプチド化合物がLHRH拮抗 薬である、請求項23の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2119996P | 1996-07-03 | 1996-07-03 | |
US60/021,199 | 1996-07-03 | ||
PCT/US1997/010816 WO1998000157A1 (en) | 1996-07-03 | 1997-07-01 | Aqueous formulations of peptides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008165927A Division JP2008291037A (ja) | 1996-07-03 | 2008-06-25 | ペプチド類の水性配合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001504442A true JP2001504442A (ja) | 2001-04-03 |
Family
ID=21802912
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50421998A Ceased JP2001504442A (ja) | 1996-07-03 | 1997-07-01 | ペプチド類の水性配合物 |
JP2008165927A Pending JP2008291037A (ja) | 1996-07-03 | 2008-06-25 | ペプチド類の水性配合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008165927A Pending JP2008291037A (ja) | 1996-07-03 | 2008-06-25 | ペプチド類の水性配合物 |
Country Status (27)
Country | Link |
---|---|
US (2) | US5916582A (ja) |
EP (1) | EP0909177B1 (ja) |
JP (2) | JP2001504442A (ja) |
CN (1) | CN1256146C (ja) |
AR (1) | AR007715A1 (ja) |
AT (1) | ATE259241T1 (ja) |
AU (1) | AU3574897A (ja) |
BR (1) | BR9710131A (ja) |
CA (1) | CA2259505A1 (ja) |
CO (1) | CO4890855A1 (ja) |
CZ (1) | CZ298464B6 (ja) |
DE (1) | DE69727572T2 (ja) |
ES (1) | ES2213828T3 (ja) |
HK (1) | HK1020677A1 (ja) |
HU (1) | HU225691B1 (ja) |
ID (1) | ID19305A (ja) |
IL (1) | IL127770A (ja) |
MY (1) | MY125556A (ja) |
NO (1) | NO323296B1 (ja) |
NZ (1) | NZ333579A (ja) |
PL (1) | PL189403B1 (ja) |
RO (1) | RO120611B1 (ja) |
RU (1) | RU2201248C2 (ja) |
SK (1) | SK284283B6 (ja) |
TW (1) | TW586932B (ja) |
WO (1) | WO1998000157A1 (ja) |
ZA (1) | ZA975943B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012525374A (ja) * | 2009-04-29 | 2012-10-22 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | GnRH類似体含有徐放配合物 |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6800071B1 (en) | 1998-10-29 | 2004-10-05 | Medtronic Minimed, Inc. | Fluid reservoir piston |
DE69943207D1 (de) | 1998-10-29 | 2011-03-31 | Medtronic Minimed Inc | Reservoiranschluss |
US20020173748A1 (en) | 1998-10-29 | 2002-11-21 | Mcconnell Susan | Reservoir connector |
US6248093B1 (en) | 1998-10-29 | 2001-06-19 | Minimed Inc. | Compact pump drive system |
US7193521B2 (en) | 1998-10-29 | 2007-03-20 | Medtronic Minimed, Inc. | Method and apparatus for detecting errors, fluid pressure, and occlusions in an ambulatory infusion pump |
US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US7063684B2 (en) | 1999-10-28 | 2006-06-20 | Medtronic Minimed, Inc. | Drive system seal |
ME00509B (me) * | 2002-09-27 | 2011-10-10 | Zentaris Gmbh | Oblik za terapijsku primjenu aktivnih peptida sa dugotrajnim oslobođenjem aktivnog sastojka i postupak za njihovo dobijanje |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
US20060039949A1 (en) * | 2004-08-20 | 2006-02-23 | Nycz Jeffrey H | Acetabular cup with controlled release of an osteoinductive formulation |
US20060045902A1 (en) * | 2004-09-01 | 2006-03-02 | Serbousek Jon C | Polymeric wrap for in vivo delivery of osteoinductive formulations |
US20060057184A1 (en) * | 2004-09-16 | 2006-03-16 | Nycz Jeffrey H | Process to treat avascular necrosis (AVN) with osteoinductive materials |
AU2006206272A1 (en) * | 2005-01-21 | 2006-07-27 | Alza Corporation | Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion |
US8137664B2 (en) * | 2005-02-02 | 2012-03-20 | Sdgi Holdings, Inc. | Method and kit for repairing a defect in bone |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
ATE509634T1 (de) * | 2005-04-08 | 2011-06-15 | Amylin Pharmaceuticals Inc | Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel |
CN100336557C (zh) * | 2005-05-11 | 2007-09-12 | 北京双鹭药业股份有限公司 | 一种生长抑素的水溶液制剂、其制备方法及应用 |
US20060287243A1 (en) * | 2005-06-17 | 2006-12-21 | Navneet Puri | Stable pharmaceutical compositions including motilin-like peptides |
US20060293243A1 (en) * | 2005-06-17 | 2006-12-28 | Navneet Puri | Stable, buffered, pharmaceutical compositions including motilin-like peptides |
BRPI0710503A2 (pt) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
DK2020990T3 (da) | 2006-05-30 | 2010-12-13 | Intarcia Therapeutics Inc | Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem |
EP2049081B1 (en) | 2006-08-09 | 2012-11-14 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
CN101715340A (zh) | 2007-04-23 | 2010-05-26 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
CA2691531C (en) | 2007-06-22 | 2016-11-01 | Board Of Regents,The University Of Texas System | Formation of stable submicron peptide or protein particles by thin film freezing |
CA2704726A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a defensin peptide as a therapeutic agent |
WO2009102467A2 (en) | 2008-02-13 | 2009-08-20 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
CA2723541A1 (en) * | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
MX2011001620A (es) | 2008-08-15 | 2011-03-25 | Ironwood Pharmaceuticals Inc | Formulaciones que contienen linaclotida para administracion oral. |
CA2743789C (en) | 2008-11-16 | 2017-10-31 | Board Of Regents, The Univesity Of Texas System | Low viscosity highly concentrated suspensions |
CA2751854A1 (en) * | 2009-02-25 | 2010-09-02 | Merrion Research Iii Limited | Composition and drug delivery of bisphosphonates |
JP2013501071A (ja) | 2009-08-06 | 2013-01-10 | アイロンウッド ファーマシューティカルズ, インコーポレイテッド | リナクロチドを含む処方物 |
JP5718925B2 (ja) | 2009-09-28 | 2015-05-13 | インターシア セラピューティクス,インコーポレイティド | 実質的な定常状態薬物送達の迅速な確立及び/又は停止 |
US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
PL2536742T3 (pl) | 2010-02-17 | 2017-11-30 | Ironwood Pharmaceuticals, Inc. | Leczenie zaburzeń żołądkowo-jelitowych |
WO2011120033A1 (en) * | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
ES2919136T3 (es) | 2010-08-11 | 2022-07-22 | Ironwood Pharmaceuticals Inc | Formulaciones estables de linaclotida |
BR112013017169A2 (pt) | 2011-01-07 | 2016-10-04 | Merrion Res Iii Ltd | composições farmacêuticas de ferro para administração oral |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
DK2776055T3 (en) | 2011-08-17 | 2017-03-06 | Ironwood Pharmaceuticals Inc | TREATMENTS FOR GASTROINTESTINAL DISORDERS |
US10112987B2 (en) | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide |
US20140271923A1 (en) | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
EP2832361A1 (en) * | 2013-07-29 | 2015-02-04 | Ipsen Pharma S.A.S. | Aqueous sustained release compositions of LHRH analogs |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
EP3250191B1 (en) | 2015-01-29 | 2024-01-17 | Novo Nordisk A/S | Tablets comprising glp-1 agonist and enteric coating |
WO2016196851A2 (en) | 2015-06-03 | 2016-12-08 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
CN105749245A (zh) * | 2016-03-02 | 2016-07-13 | 张光泉 | 抗癌药醋酸地加瑞克注射液及其制备方法 |
WO2017200943A1 (en) | 2016-05-16 | 2017-11-23 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
KR20190104039A (ko) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3914412A (en) * | 1973-10-11 | 1975-10-21 | Abbott Lab | {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity |
US4248864A (en) * | 1979-08-30 | 1981-02-03 | American Home Products Corporation | Reproduction control |
DE3371281D1 (en) * | 1982-12-10 | 1987-06-11 | Syntex Inc | Lhrh preparations for intranasal administration |
US4547370A (en) * | 1983-11-29 | 1985-10-15 | The Salk Institute For Biological Studies | GnRH Antagonists |
US4661472A (en) * | 1985-05-09 | 1987-04-28 | The Salk Institute For Biological Studies | GnRH antagonists IX |
US4851385A (en) * | 1987-07-15 | 1989-07-25 | Indiana University Foundation | LHRH antagonist analogs having low histamine-release activity |
US4800191A (en) * | 1987-07-17 | 1989-01-24 | Schally Andrew Victor | LHRH antagonists |
DD273980B5 (de) * | 1988-07-12 | 1994-04-14 | Berlin Chemie Ag | Verfahren zur Herstellung von Insulin-Pr{paraten zur rektalen Anwendung |
US5110596A (en) * | 1988-12-13 | 1992-05-05 | Alza Corporation | Delivery system comprising means for delivering agent to livestock |
US5034229A (en) * | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
US5057318A (en) * | 1988-12-13 | 1991-10-15 | Alza Corporation | Delivery system for beneficial agent over a broad range of rates |
DE4117507A1 (de) * | 1991-05-24 | 1992-11-26 | Schering Ag | Verfahren zur herstellung von n(pfeil hoch)6(pfeil hoch)-substituierten lysin-derivaten |
US5446025A (en) * | 1992-06-12 | 1995-08-29 | Abbott Laboratories | Formulations and method of the percutaneous administration of leuprolide |
TW333456B (en) * | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
PT686045E (pt) * | 1993-02-23 | 2001-04-30 | Genentech Inc | Estabilizacao por excipientes de polipeptidos tratados com solventes organicos |
DE4320201A1 (de) * | 1993-06-18 | 1995-01-12 | Asta Medica Ag | Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation |
US5482931A (en) * | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
CZ282456B6 (cs) * | 1993-06-29 | 1997-07-16 | Ferring B. V. | Kompozice pro nasální podání desmopressinu |
US5413990A (en) * | 1993-08-06 | 1995-05-09 | Tap Pharmaceuticals Inc. | N-terminus modified analogs of LHRH |
US5595760A (en) * | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
PT1238660E (pt) * | 1996-02-02 | 2005-10-31 | Alza Corp | Distribuicao sustentada de um agente activo utilizando um sistema implantavel |
-
1997
- 1997-06-13 US US08/874,694 patent/US5916582A/en not_active Expired - Lifetime
- 1997-06-28 MY MYPI97002941A patent/MY125556A/en unknown
- 1997-07-01 RO RO98-01770A patent/RO120611B1/ro unknown
- 1997-07-01 PL PL97330903A patent/PL189403B1/pl not_active IP Right Cessation
- 1997-07-01 NZ NZ333579A patent/NZ333579A/en not_active IP Right Cessation
- 1997-07-01 EP EP97932237A patent/EP0909177B1/en not_active Expired - Lifetime
- 1997-07-01 IL IL127770A patent/IL127770A/en not_active IP Right Cessation
- 1997-07-01 CN CNB971960526A patent/CN1256146C/zh not_active Expired - Fee Related
- 1997-07-01 AU AU35748/97A patent/AU3574897A/en not_active Abandoned
- 1997-07-01 AT AT97932237T patent/ATE259241T1/de not_active IP Right Cessation
- 1997-07-01 RU RU99102246/14A patent/RU2201248C2/ru not_active IP Right Cessation
- 1997-07-01 CZ CZ0433998A patent/CZ298464B6/cs not_active IP Right Cessation
- 1997-07-01 SK SK1798-98A patent/SK284283B6/sk not_active IP Right Cessation
- 1997-07-01 DE DE69727572T patent/DE69727572T2/de not_active Expired - Lifetime
- 1997-07-01 HU HU0000589A patent/HU225691B1/hu not_active IP Right Cessation
- 1997-07-01 CA CA002259505A patent/CA2259505A1/en not_active Abandoned
- 1997-07-01 ES ES97932237T patent/ES2213828T3/es not_active Expired - Lifetime
- 1997-07-01 JP JP50421998A patent/JP2001504442A/ja not_active Ceased
- 1997-07-01 BR BR9710131A patent/BR9710131A/pt not_active Application Discontinuation
- 1997-07-01 WO PCT/US1997/010816 patent/WO1998000157A1/en active IP Right Grant
- 1997-07-02 AR ARP970102966A patent/AR007715A1/es unknown
- 1997-07-03 ID IDP972313A patent/ID19305A/id unknown
- 1997-07-03 ZA ZA9705943A patent/ZA975943B/xx unknown
- 1997-07-03 CO CO97037100A patent/CO4890855A1/es unknown
- 1997-08-22 TW TW086109391A patent/TW586932B/zh active
-
1998
- 1998-12-30 NO NO19986208A patent/NO323296B1/no not_active IP Right Cessation
-
1999
- 1999-02-11 US US09/248,286 patent/US6068850A/en not_active Expired - Lifetime
- 1999-12-09 HK HK99105751A patent/HK1020677A1/xx not_active IP Right Cessation
-
2008
- 2008-06-25 JP JP2008165927A patent/JP2008291037A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012525374A (ja) * | 2009-04-29 | 2012-10-22 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | GnRH類似体含有徐放配合物 |
US8962559B2 (en) | 2009-04-29 | 2015-02-24 | Ipsen Pharma S.A.S. | Sustained release formulations comprising GNRH analogues |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001504442A (ja) | ペプチド類の水性配合物 | |
JP2001504802A (ja) | 非水性プロトン性ペプチド配合物 | |
RU2203084C2 (ru) | Стабильный неводный препарат пептидного соединения (варианты), способ его получения (варианты) и способ лечения гормон-зависимого заболевания у субъекта (варианты) | |
US5981489A (en) | Non-aqueous protic peptide formulations | |
KR100594519B1 (ko) | 비수성양성자성펩티드제제 | |
AU2004242540B2 (en) | Aqueous formulations of peptides | |
KR100517091B1 (ko) | 펩티드의수성제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040506 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070508 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070808 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070914 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080122 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080226 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080527 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080625 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080611 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080821 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20080828 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091005 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091016 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110608 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110617 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110708 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110720 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110808 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110816 |